On October 26, 2023 the IVAN Users Group hosted a meeting on NMR in the World of Fragmented Drug Design.
The panel was lead by Daneen Angwin-Kaerner of Loxo@Lilly, and presentations were done by Andrew Namanja of Abbvie Inc. and Ben Davis of Vernalis Research.
NMR has evolved into a powerful tool for fragment-based drug discovery over the last two decades. While NMR has been traditionally used to elucidate structure and dynamics of macromolecules, it is also be a very valuable tool for the reliable identification of small molecules that bind to biomolecules and for hit-to-lead optimization. In this workshop, we will discuss the use of NMR as a method for fragment-based drug discovery and how to utilize this approach for discovering novel therapeutics.